Taking people in SwitzerlandNo phase
Extended Versus No Lymph Node Removal During Prostate Surgery
Tests extended lymph node removal during prostate surgery in men with prostate cancer.
Key facts
- Who runs it
- University Hospital, Basel, Switzerland
- Where
- Aarau, Basel, Bern, Biel, Chur, Geneva, Lausanne, Liestal, Lucerne, Lugano, Neuchâtel, Sankt Gallen, and Zurich, SwitzerlandSee the 15 sites
- Trial code
- Registry title
- Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 10 Feb 2025
- Expected to end
- Feb 2040
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Extended Pelvic Lymph Node Dissection
- Record updated
- 3 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with high-risk prostate cancer whose PSMA-PET scan shows no spread, and who are planned for surgery to remove the prostate.
- Age
- 18 years or older, with a life expectancy of more than 15 years.
- Sex
- Men only.
- Disease stage
- High-risk prostate cancer: biopsy-proven WHO/ISUP grade group III-V, or grade group II with PSA above 20 ng/ml. The PSMA-PET scan must show no spread to nearby or distant sites.
- Earlier treatment
- No earlier treatment for prostate cancer, no earlier pelvic lymph node removal and no earlier pelvic radiotherapy.
- Biomarker or test result
- PSMA-PET scan negative for regional and distant spread.
Main reasons for not taking part
- Grade group I cancer with cT1 or cT2 on MRI
- cT4 cancer on MRI
- Positive PSMA-PET for local or distant spread
- Any earlier treatment for prostate cancer
- Earlier pelvic lymph node removal or pelvic radiotherapy
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age ≥ 18 years and life expectancy >15 years
- Any biopsy-proven WHO/ISUP grade groups III-V PCa
- High-risk prostate cancer defined as:; Any biopsy-proven WHO/ISUP grade group III-V PCa or; ISUP grade group II and PSA > 20 ng/ml
- PSMA-PET: negative staging for regional and distant metastasis
- multidisciplinary tumorboard recommendation for radical prostatectomy
- WHO performance status 0-1
- Adequate condition (ASA ≤ III) for general anesthesia and RP
Who cannot take part
- Any prior neoadjuvant, local or systemic treatment for PCa
- Previous PLND or pelvic radiotherapy
- Patients with a prior malignancy and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence
- Any other serious underlying medical, psychiatric, psychological, familial, or geographical
- condition, which in the judgment of the investigator may interfere with the planned
- ISUP grade group I PCa and cT1 or cT2 (MRI)
- cT4 (MRI) PCa
- PSMA-PET: positive staging for local and distant metastasis
- staging, treatment and follow-up, which affect patient compliance or place the patient at
- high risk from treatment-related complications
- Vulnerable men (participants incapable of judgment or participants under tutelage) will not be included in the study
Where in Switzerland
- Cantonal Hospital AarauAarau, SwitzerlandContact: Lukas Prause, DrTaking people
- University Hospital BaselBasel, SwitzerlandContact: Cyrill Rentsch, Prof. Dr. med.Taking people
- InselspitalBern, SwitzerlandContact: Beat Roth, Prof. Dr.Taking people
- Lindenhof HospitalBern, SwitzerlandContact: Silvan Boxler, DrTaking people
- Cantonal Hospital BielBiel, SwitzerlandContact: Roland Seiler-Blarer, ProfTaking people
- Cantonal Hospital ChurChur, SwitzerlandContact: Räto Strebel, PD. Dr.Taking people
- University Hospital GenevaGeneva, SwitzerlandContact: Massimo Valerio, Prof. Dr.Taking people
- Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, SwitzerlandContact: Ilaria Lucca, PD. Dr.Taking people
- Cantonal Hospital LiestalLiestal, SwitzerlandContact: Svetozar Subotic, DrTaking people
- Cantonal Hospital LuzernLucerne, SwitzerlandContact: Christian Fankhauser, Prof. Dr.Taking people
- Ospedale Regionale di LuganoLugano, SwitzerlandContact: Andrea Gallina, Prof. Dr.Taking people
- Cantonal Hospital NeuchâtelNeuchâtel, SwitzerlandContact: Daniel Nguyen, PD. Dr.Taking people
- Cantonal Hospital St GallenSankt Gallen, SwitzerlandContact: Daniel Engeler, Prof. Dr.Taking people
- Hospital Triemli, ZürichZurich, SwitzerlandContact: Michael Müntener, Prof. Dr.Taking people
- University Hospital ZurichZurich, SwitzerlandContact: Ashkan Mortezavi, PD. Dr.Taking people
About the trial
What the trial wants to find out
The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.
The 2 groups in the trial
- Radical prostatectomy with extended pelvic lymph node dissectionTreatment being tested
Treatment: Extended Pelvic Lymph Node Dissection
- Radical prostatectomy without extended pelvic lymph node dissectionNo study treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Extended Pelvic Lymph Node Dissection vs. No Pelvic Lymph Node Dissection at Radical Prostatectomy in PSMA PET Negative Staged Men: A Multicenter, Randomized Phase III Trial
- Plain-language title
- Extended Versus No Lymph Node Removal During Prostate SurgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 July 2025